Insider Monkey
JPMorgan Raises Cogent Biosciences (COGT) PT to $67 on Sector Model Update
📈
AI Sentiment
Highly Positive
9/10
- Home
- COGT
as of 12-31-2025 2:15pm EST
$36.00
$1.12
-3.02%
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | WALTHAM |
| Market Cap: | 6.5B | IPO Year: | 2018 |
| Target Price: | $30.00 | AVG Volume (30 days): | 2.5M |
| Analyst Decision: | Buy | Number of Analysts: | 13 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.47 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.72 - $43.73 | Next Earning Date: | 11-03-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
AI-Powered COGT Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 20 hours ago
AI Recommendation
hold
Model Accuracy: 75.16%
75.16%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Cogent Biosciences Inc. (COGT)
Robinson John Edward
Sell
Chief Scientific Officer
COGT Dec 26, 2025
Avg Cost/Share
$38.74
Shares
90,000
Total Value
$3,486,600.00
Owned After
140,002
SEC Form 4
Green John L.
Sell
Chief Financial Officer
COGT Dec 26, 2025
Avg Cost/Share
$38.68
Shares
77,000
Total Value
$2,978,360.00
Owned After
131,834
SEC Form 4
Kearns Evan
Sell
Chief Legal Officer
COGT Dec 26, 2025
Avg Cost/Share
$38.70
Shares
65,000
Total Value
$2,515,500.00
Owned After
109,398
SEC Form 4
Sachs Jessica
Sell
Chief Medical Officer
COGT Dec 26, 2025
Avg Cost/Share
$38.70
Shares
82,642
Total Value
$3,198,245.40
Owned After
133,938
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Robinson John Edward | COGT | Chief Scientific Officer | Dec 26, 2025 | Sell | $38.74 | 90,000 | $3,486,600.00 | 140,002 | |
| Green John L. | COGT | Chief Financial Officer | Dec 26, 2025 | Sell | $38.68 | 77,000 | $2,978,360.00 | 131,834 | |
| Kearns Evan | COGT | Chief Legal Officer | Dec 26, 2025 | Sell | $38.70 | 65,000 | $2,515,500.00 | 109,398 | |
| Sachs Jessica | COGT | Chief Medical Officer | Dec 26, 2025 | Sell | $38.70 | 82,642 | $3,198,245.40 | 133,938 |
Latest Cogent Biosciences Inc. News
COGT Breaking Stock News: Dive into COGT Ticker-Specific Updates for Smart Investing
Compare COGT vs Leading Stocks
See how COGT stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "COGT Cogent Biosciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.